Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Combination vs single‐agent chemotherapy

Time to progression · people with advanced gastric cancer

Combination probably leads to lower time to progression compared with single‐agent chemotherapy (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.69 [0.55, 0.87]
4 studies · 720 participants
Moderate

5‐FU/cisplatin/anthracycline combinations vs 5‐FU/cisplatin combinations (without anthracyclines)

Time to progression · people with advanced gastric cancer

5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.62 [0.38, 0.98]
1 study · 78 participants
Low